Loreto Fernandez

Nephrologist at Clinica Universidad de Navarra #Medicine, #Nephrology and #ArTlover

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

Not all #IgAN therapies are created equal
#Nephpearls #RKDSummit

👉🏼 https://t.co/LcVHVrLlT9

[NEJM @NEJM]

Our latest video in partnership with @DGlaucomflecken summarizes the ALLEGORY trial that evaluated the efficacy and safety of obinutuzumab when added to standard therapy in adults with active systemic lupus erythematosus. Read the full study for free: https://t.co/Yxfw2Hgkom

#rheumatology

[NEJM @NEJM]

Original Article: Sodium Bicarbonate for Critically Ill Adults with Metabolic Acidosis and Shock (SODa-BIC trial) https://t.co/uTtuin6rig

Editorial: Sodium Bicarbonate in Critical Illness — A New Chapter for the Book https://t.co/pywzzcAkVV

#Nephrology #EmergencyMedicine

[Kenar Jhaveri @kdjhaveri]

Bispecific Antibodies for Glomerular Diseases: Are We Ready for Prime Time? https://t.co/Gtp0LzN02f @ISGDtweets @asnpublications @GlomCon @SabineKaram6 @BoudhabhayI

[Grace Choung, MD 박영이 @grace_choung]

Complement in Kidney Disease: Core Curriculum 2026 - American Journal of Kidney Diseases https://t.co/C2hmAQQSFi

[NDT @NDTsocial]

🧐Pro / Con:

Hematuria as a biomarker guiding treatment decisions in IgA nephropathy? No

https://t.co/HNKPsFmPrv

Hematuria as a biomarker guiding treatment decisions in IgA nephropathy? Yes

https://t.co/dfNCz0hKJ4

[Intissar HADDIYA @HaddiyaIntissar]

🩺 In primary membranous #nephropathy, real-world #CureGN data suggest better long-term kidney function preservation with #rituximab than with #calcineurin_inhibitors (progression HR 2.81 for CNIs).
#Nephrology #Rituximab #KidneyHealth @AfricanAFRAN @ISNkidneycare

[Nature Reviews Drug Discovery @NatRevDrugDisc]

For readers interested in the opportunities and pitfalls for CAR-T therapies for autoimmune diseases, here's a recent comprehensive review https://t.co/RNbKBGRrgm
https://t.co/b3JOpR4MI7

[S.E.N. Nefrología @SENefrologia]

💥 NUEVA plataforma Comunidad Virtual en Glomerulopatías👇
🧬 Regístrate y forma parte de la comunidad
🔗 https://t.co/K4gu7CWYUc
👉 ¿Qué encontrarás?
💬 Posts sobre novedades y casos clínicos reales
🎥 Webinars exclusivos
🏆 Concursos de casos clínicos
📊 Encuestas formativas
✅ Avalado por @SEAP_IAP y AENP, con la colaboración de la @SENefrologia y @NovartisSpain

[NEJM @NEJM]

Well, it depends... who do you want to yell at you? Cardiology or Nephrology?

Our latest video in partnership with @DGlaucomflecken summarizes the ARISE FLUIDS trial that examined whether hemodynamic resuscitation with early vasopressors versus more liberal fluids could affect outcomes in patients with septic shock. Read the full study for free: https://t.co/wCpW1oJ6As

#emergencymedicine

[Jonathan Zuckerman MD PhD @JZRenalPath]

Fibrillary GN with linear staining potentially mimicking anti-GBM. Mesangial staining + mesangial expansion by silver weak material not typical for anti-GBM. Also only focal crescents. fibrils infiltrating GBM on EM. #renalpath #pathtwitter #nephrology

[AJKD @AJKDonline]

NEW on the #AJKDBlog:

@Maximal_Change interviews @DanaRizk1 on B-Cell Modulators in IgA Nephropathy https://t.co/croRoOIz8t

[Juan Manuel Mejía @Meyaix]

These PRO vs. CON discussions are a great way to critically evaluate emerging tx strategies. I recommend this debate on combination ("triple") therapy for #lupusnephritis. Ultimately, the goal is to define the best personalized treatment for each patient https://t.co/pHboNoL1Hp

[Nature Reviews Nephrology @NatRevNeph]

Disease modification in lupus nephritis: towards a pathophysiology-based treatment paradigm https://t.co/pM4MAsRlMW

[ASN Publications @asnpublications]

For patients with IgA nephropathy, telitacicept produces a sustained reduction in proteinuria while slowing the decline in kidney function, according to a preliminary clinical trial report in The New England Journal of Medicine. Read a recap of the findings in #ASNKidneyNews: https://t.co/eeBLg1je3Q

[Hans-Joachim Anders @hjanders_hans]

Now online in @NDTsocial

Impact of immunosuppressive therapy in rapidly progressive secondary IgAN

🧐Treatment escalation was not associated with improved renal or patient survival

▶️https://t.co/PmokXljXFF

[S.E.N. Nefrología @SENefrologia]

🧬 NUEVA plataforma de la Comunidad Virtual en Glomerulopatías
👥 Para especialistas en enfermedades renales y sistémicas:
👨‍⚕️ Resuelve dudas con un panel de expertos multidisciplinar
📚 Comparte y comenta casos clínicos reales
🎥 Webinars exclusivos
💻 Accede a la nueva plataforma para no perderte ninguna novedad:
🔗 https://t.co/USxyS87fEb

✅ Avalado por @SEAP_IAP y AENP, con la colaboración de la @SENefrologia y @NovartisSpain

👥 Panel de Expertos Multidisciplinar: Dr. Manuel Praga, Dr. Xavier Fulladosa, Dr. Eduardo Gutiérrez, Dra. Gema Ariceta y Dr. Francisco Díaz.
🗣️ Expertos Dinamizadores: Dra. Juliana Bordignon, @VirginiaCabel10, @fcaravacafontan, Dra. Mar Espino, Dr. Mario Espinosa, @gemafdez_lapaz, Dra. Mª Loreto Fernández, Dra. Adriana García, @eugegarfer, @mmacia25, Dr. Luis Quintana, @PepaSolerR, Dr. Luis Alberto Vigara y Dr. Javier Villacorta.

[KIReports @KIReports]

Circulating #Antinephrin Antibodies in Adult #Chinese Patients With #IgAN and Nephrotic-Range Proteinuria

#VisualAbstract by @brian_rifkin

https://t.co/zFDnvjfqQ6

[Andreas Kronbichler @AKronbichler]

A sad day for vasculitis, patients and caregivers. A relevant tool has been taken away - however, data integrity of clinical trials is key!

Nonetheless, we need to start moving away from BVAS as endpoint! It is time …

https://t.co/lCc9pIvyBv

[NDT @NDTsocial]

Pathophysiology of pregnancy-associated acute kidney injury

https://t.co/YxuZpHhbJ4